MedTrace Logo

Fibroblast Growth Factor 23 and Sclerostin in Relation to Calcium in COVID-19 Patients

NCT05275491 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2023-02-14

No results posted yet for this study

Summary

Hypocalcemia is associated with COVID-19 patients and is linked to poor prognosis, Fibroblast growth factor 23 (FGF23) and Sclerostin inhibit vitamin D activation and are linked to hypocalcemia.

Levels of FGF23 and Sclerostin in COVID-19 patients will be detected and correlated to calcium levels.

Conditions

Interventions

DIAGNOSTIC_TEST

Calcium

Free calcium serum levels

DIAGNOSTIC_TEST

Fibroblast growth factor 23

Serum level

DIAGNOSTIC_TEST

Sclerostin

Serum level

DIAGNOSTIC_TEST

parathyroid hormone

serum level

Sponsors & Collaborators

  • Aswan University Hospital

    lead OTHER

Principal Investigators

  • Asmaa Abdelmageed Muhammed, Lecturer · Aswan University Hospital

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2023-01-01
Completion
2023-02-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05275491 on ClinicalTrials.gov